SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 426 filers reported holding SAREPTA THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.00 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $7,698 | +906.3% | 48,721 | +724.7% | 0.07% | +842.9% |
| Q1 2024 | $765 | -56.3% | 5,908 | -67.5% | 0.01% | -50.0% |
| Q4 2023 | $1,752 | -29.4% | 18,168 | -11.3% | 0.01% | -33.3% |
| Q3 2023 | $2,483 | +12.7% | 20,482 | +6.5% | 0.02% | +16.7% |
| Q2 2023 | $2,203 | -9.7% | 19,239 | +8.7% | 0.02% | -14.3% |
| Q1 2023 | $2,439 | -3.4% | 17,699 | -9.1% | 0.02% | -8.7% |
| Q4 2022 | $2,524 | -99.9% | 19,476 | +1.3% | 0.02% | +9.5% |
| Q3 2022 | $2,126,000 | +49.9% | 19,235 | +1.6% | 0.02% | +61.5% |
| Q2 2022 | $1,418,000 | -5.3% | 18,923 | -1.3% | 0.01% | +8.3% |
| Q1 2022 | $1,498,000 | -52.1% | 19,175 | -44.8% | 0.01% | 0.0% |
| Q4 2021 | $3,130,000 | +144.9% | 34,764 | +151.6% | 0.01% | +9.1% |
| Q3 2021 | $1,278,000 | +12.1% | 13,818 | -5.7% | 0.01% | +22.2% |
| Q2 2021 | $1,140,000 | +9.2% | 14,659 | +4.6% | 0.01% | -76.9% |
| Q1 2021 | $1,044,000 | -59.8% | 14,009 | -8.0% | 0.04% | -60.2% |
| Q4 2020 | $2,597,000 | +22.9% | 15,232 | +1.2% | 0.10% | +6.5% |
| Q3 2020 | $2,113,000 | -14.6% | 15,050 | -2.5% | 0.09% | -20.0% |
| Q2 2020 | $2,475,000 | +36.0% | 15,437 | -17.0% | 0.12% | +161.4% |
| Q1 2020 | $1,820,000 | -26.3% | 18,608 | -2.8% | 0.04% | -2.2% |
| Q4 2019 | $2,471,000 | +85.8% | 19,146 | +8.4% | 0.04% | +60.7% |
| Q3 2019 | $1,330,000 | -43.9% | 17,661 | +13.2% | 0.03% | -49.1% |
| Q2 2019 | $2,370,000 | +31.2% | 15,598 | +2.9% | 0.06% | +25.0% |
| Q1 2019 | $1,807,000 | +11.3% | 15,158 | +1.9% | 0.04% | -4.3% |
| Q4 2018 | $1,623,000 | +17.2% | 14,874 | +73.5% | 0.05% | +35.3% |
| Q3 2018 | $1,385,000 | -27.6% | 8,574 | -40.7% | 0.03% | -27.7% |
| Q2 2018 | $1,912,000 | +217.1% | 14,466 | +77.7% | 0.05% | +193.8% |
| Q1 2018 | $603,000 | +30.8% | 8,140 | -1.7% | 0.02% | +33.3% |
| Q4 2017 | $461,000 | +35.6% | 8,281 | +10.4% | 0.01% | +9.1% |
| Q3 2017 | $340,000 | +52.5% | 7,498 | +13.2% | 0.01% | +57.1% |
| Q2 2017 | $223,000 | -19.8% | 6,625 | +46.5% | 0.01% | -56.2% |
| Q3 2016 | $278,000 | – | 4,521 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Asymmetry Capital Management, L.P. | 87,180 | $2,581,000 | 3.60% |
| Perceptive Advisors | 1,771,029 | $52,422,000 | 2.99% |
| SPHERA FUNDS MANAGEMENT LTD. | 483,047 | $14,298,000 | 2.80% |
| HealthCor Management, L.P. | 1,550,000 | $45,880,000 | 2.10% |
| Camber Capital Management LP | 1,350,000 | $39,960,000 | 1.62% |
| Tourbillon Capital Partners, L.P. | 1,537,518 | $45,511,000 | 1.17% |
| Elk Creek Partners, LLC | 562,522 | $16,651,000 | 1.02% |
| EMERALD ADVISERS, LLC | 818,705 | $24,234,000 | 1.00% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 604,467 | $17,892,000 | 0.82% |
| Carlson Capital, L.P. | 1,845,702 | $54,633,000 | 0.70% |